Status:
RECRUITING
Pan Tumor Rollover Study
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Exelixis
Novartis
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Eligibility Criteria
Inclusion Criteria
- Signed Written Informed Consent.
- Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
- On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
- WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
Exclusion Criteria
- Participant is not eligible for study treatment per the Parent Study eligibility criteria.
- Participants not receiving clinical benefit as assessed by the Investigator.
- Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
- Other protocol-defined Inclusion/Exclusion Criteria apply
Key Trial Info
Start Date :
August 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 25 2029
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT03899155
Start Date
August 9 2019
End Date
August 25 2029
Last Update
April 1 2026
Active Locations (399)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0220
Huntsville, Alabama, United States, 35801
2
University of Arizona College of Medicine
Tucson, Arizona, United States, 85724
3
Innovative Clinical Research Institute
Lynwood, California, United States, 90262
4
Local Institution
San Francisco, California, United States, 94115